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of parotid adenocarcinomas?Cristiana Bergamini a, Marta Barisella b, Laura D. Locati a, Paolo Bossi a,
Paolo Potepan c, Gaetana Rinaldi a, Lisa Licitra a,*a Head and Neck Cancer Medical Oncology Unit, Medical Department, Istituto Nazionale Tumori
Via G. Venezian 1 Milan, Italy
b Pathology Unit B, Istituto Nazionale Tumori Via G. Venezian 1 Milan, Italy
c Radiology Department, Istituto Nazionale Tumori Via G. Venezian 1 Milan, ItalyReceived 2 March 2005; accepted 8 June 2005Summary We report the case of a patient with Androgen’s Receptor (AR) and PSA
positive parotid adenocarcinoma, who developed skeletal and bone marrow lesions
in presence of elevated seric PSA values (142 lg/L). The tumor cells infiltrating the
bone marrow were found positive for both AR and PSA, mimicking clinical and immu-
nohistochemical metastases from prostate cancer, which was definitively ruled out.
These observations suggest that in salivary gland metastatic AR-positive carcinomas
seric PSA evaluation might be useful for the disease monitoring. Androgen depriva-
tion, previously reported as beneficial in a few cases, should be further investigated.c 2005 Published by Elsevier Ltd.
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2In November 2000, a 68-year old man with
pT3N2b parotid adenocarcinoma underwent a right
parotidectomy including mandibular resection,
right neck dissection. Postoperative radiation
followed.
The submandibular gland specimen comprised
hemimandibular bone partially covered by mucosa,
submandibular gland and laterocervical soft tis-
sues. A whitish solid ill-defined 2 cm tumor mass741-9409/$ - see front matter c 2005 Published by Elsevier Ltd.
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E-mail address: lisa.licitra@istitutotumori.mi.it (L. Licitra).centered in the submandibular gland extended into
bone and skeletal muscle. The mass was micro-
scopically composed of tumor cells widely infiltrat-
ing a desmoplastic stroma and perineural spaces.
The tumor cells were arranged singly or in strands,
sometimes clustered in small nests or forming glan-
dular structures with small lumina filled with prote-
inaceus material. They were medium sized, with
finely vacuolated cytoplasm and large nuclei, often
containing conspicuous nucleoli. Mitosis was
scanty. There was an infiltration of reactive mono-
nuclear cells. In June 2001 a parenchymal peri-ilar
lung lesion with nodal ilar enlargement and bone
220 C. Bergamini et al.lesions were detected: conventional irradiation on
the cervical spine and stereotactic irradiation to
the lung were administered.
On the primary tumor specimen a 100% andro-
gen’s receptor (AR) positivity and a positivity for
PSA was shown (Fig. 1). PSAP immunostain was
not performed.
Based on these findings in December 2001 a
therapy with bicalutamide, and triptoreline was
started. Serum PSA values were normal.
In August 2002 a new lytic lesion in the left
humerus was detected microscopically similar to
the parotid tumor. This was associated with pro-
gression of the lung lesions. The left humerus and
the lung were further irradiated. Deprivative hor-
monal therapy was stopped.
From May 2003 till October 2003 an increasing
and diffuse skeletal involvement was evident. Pal-
liative chemotherapy and zoledronic acid were
started.
Because of a chemotherapy-related normocro-
mic microcytic anemia, a bone marrow biopsy
was performed, which revealed diffuse infiltration
by adenocarcinoma cells. Cancer cells showed a
strong cytoplasmatic PSA and AR positivity but
were negative for PSAP (Fig. 2). The marked mor-Figure 1 The salivary gland adenocarcinoma was com-
posed of tumor cells with finely vacuolated cytoplasm,
arranged singly or in strands (A), with strong androgen
receptor (B) and PSA (C) immunoreactivity.phologic and immunohistochemical similarities be-
tween the primary tumor and the bone lesions
suggested a common origin. Besides, a peak serum
level of PSA of 142 lg/L was detected. In order to
rule out a second prostatic primary the patient
underwent an extensive clinical, radiographical
and pathological examination, with negative
results.
We concluded that we were dealing with a bone
marrow infiltration from the parotid adenocarci-
noma, which clinically and immunohistochemically
simulated a metastatic prostatic cancer.
Major salivary gland adenocarcinoma is rare,
accounting for 16% of all parotid cancers. Some
of them express androgen receptors and consis-
tently show a positive immunohistochemical reac-
tion to prostate-specific antigen (PSA).1–5
A case of metastatic salivary duct cancer with
elevated serum level of PSA was reported.5 In our
patient, the PSA level increase was associated with
tumor progression. Similarly to prostate cancer,
a serum peak in PSA proved useful, even in moni-
toring patients with AR-positive salivary gland
adenocarcinomas. In salivary gland metastatic
AR-positive carcinoma, androgen deprivation is
beneficial and should be further investigated.6,7Figure 2 The bone biopsy show infiltration of the
marrows spaces by medium sized tumor cells with
microvacuolated cytoplasm and scattered prominent
nucleoli (A), with strong androgen receptor (B) and PSA
(C) immunoreactivity.
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